Израиль еліндегі үздік Иммунотерапия Кейтрудой (Пембролизумаб) дәрігерлердің бағаларын салыстырыңыз. Өз үздік сәйкестіңізді осы жерден табыңыз.

Дәрігер қызметтеріне ең жақсы баға ұсынатын елді таңдаңыз

Үздік елдердегі Иммунотерапия Кейтрудой (Пембролизумаб) бағаларын салыстырыңыз

Үздік дәрігерлер мен бағаны көру үшін елді түртіңіз

Turkey

Ukraine

South Korea

Mexico

Czech Republic

Canada

$3,300 - $10,000

$4,500 - $8,000

$5,200 - $8,500

$7,000 - $11,000

$7,500 - $10,500

$7,800 - $11,200

$2,000

$4,000

$6,000

$8,000

$10,000

$12,000

Тегін жеке емдеу жоспарын алыңыз және ең жақсы нұсқаны таңдаңыз. Міндеттеме жоқ · Біздің қызметтер үшін төлем болмайды

Gil Bar-Sela

Орналасқан жері: Израиль, Хайфа
Клиника:
5.0
Rambam Medical Center
Рамбам медициналық орталығы онкология бөлімінің меңгерушісінің орынбасары – доктор Бар-Села қатерлі ісік ауруларын емдеудің озық әдістеріне маманданған.
- Кейтруданы (пембролизумаб) қолданатын иммунотерапия бойынша сарапшы
- Қатерлі ісікті жеке емдеу жоспарларына баса назар аударады
- Израильдегі жетекші онкология бөлімінде жұмыс істейді
Толығырақ оқу

Дәрігерге бару

Бағасы сұрау бойынша

Bookimed сараптамасы: Израильдің еліндегі жетекші иммунотерапияның кейтрудой (пембролизумаб) мамандары (2026)

Bookimed Израильдің елінде Иммунотерапия Кейтрудой (Пембролизумаб) бойынша 15 сұранысты үйлестірді, 1 маманмен жұмыс істейді. Осы кестедегі дәрігерлер өз біліктілігімен және науқастардың ерекше қажеттіліктерін шешудегі тәжірибесімен ерекшеленіп тұрады. 2026 рейтингінде барлық ақпарат нақты науқастардың жағдайлары мен серіктес клиникалардың ағымдағы бағдарламаларынан алынған растаулы деректерге негізделген.

Рейтинг	Дәрігер	тәжірибе	Сәйкес келеді үшін	Оларды өзгелерден ерекшелендіретін ерекшеліктері	Клиника және орны	Консультация
#1	Gil Bar-Sela		Иммунотерапиялық емдеу	Израильдің жетекші медициналық орталықтарының бірінде Кейтруда препаратымен иммунотерапияға маманданған. Онкология бөлімінің меңгерушісінің орынбасары.	Rambam Medical Center Израиль	Бағасы сұрау бойынша

FAQ

Бұл Bookimed арқылы медициналық көмек іздейтін нақты науқастардың сұрақтары. Оларға тәжірибелі дәрігер-координаторлар мен клиникалардың ресми өкілдері жауап береді.

Which Israeli hospitals have the most active immunotherapy programs with Keytruda?

Sourasky Medical Center and Hadassah Medical Center lead Israel's immunotherapy landscape with extensive Keytruda programs. These institutions feature dedicated oncology divisions and specialized research units. They provide access to advanced protocols for melanoma, lung cancer, and gastrointestinal malignancies through international clinical trials and expert coordination.

Specialized oncology divisions: Sourasky (Ichilov) houses the first laboratory accredited for PD-L1 expression testing.
Gastrointestinal expertise: Dr. Auala Hubert at Hadassah leads immunotherapy for complex digestive system cancers.
Pediatric programs: Dana Dwek Children's Hospital at Sourasky offers specialized immunotherapy for pediatric oncology.
Advanced sarcoma treatment: Professor Ofer Merimsky pioneers Keytruda protocols for complex bone and soft tissue tumors.

Bookimed Expert Insight: Data shows that Sourasky Medical Center is a premier hub for complex cases due to its multi-disciplinary leadership. Dr. Ido Wolf chairs the National Council for Oncology, while Dr. David Sarid, trained at Oxford, leads clinical trials. This concentration of national leadership and international training allows patients to access treatment plans that align with the latest global standards.

Patient Consensus: Patients note that arriving with your own pathology slides can help avoid diagnostic delays in the busy Tel Aviv centers. Many describe a feeling of deep relief when accessing compassionate-use programs for advanced cancers in Jerusalem. Those who traveled to Israel emphasize that having a coordinator is vital to navigate the hospital bureaucracy quickly.

What criteria do Israeli doctors use to decide if a patient is eligible for Keytruda?

Israeli oncologists determine Keytruda eligibility by evaluating tumor biomarkers, specific cancer types, and previous treatment results. They prioritize genetic profiling and PD-L1 expression levels to confirm the therapy will be effective. Doctors also check if the patient meets the strict criteria outlined in the national health basket.

Biomarker testing: Doctors require evidence of PD-L1 expression, often at thresholds of 1% or 50%.
Genetic profiling: Eligibility often depends on Microsatellite Instability-High (MSI-H) or high Tumor Mutational Burden (TMB-H).
Cancer indications: Treatment is typically approved for advanced melanoma, non-small cell lung cancer, and HNSCC.
Treatment history: For some cancers, patients must first show resistance to standard chemotherapy or surgery.

Bookimed Expert Insight: Israeli specialists often combine clinical practice with genomic research to refine eligibility. For instance, Dr. Ari Raphael at Sourasky Medical Center serves as a principal investigator for Keytruda clinical trials. This dual role allows doctors to use NGS interpretation and T-cell studies to identify eligibility for patients who might not meet standard criteria. Consultations with experts like Dr. Irina Stepfansky, starting from $750, often include reviews of Phase I-III trial opportunities.

Patient Consensus: Patients note that having clear genetic test results like FoundationOne is essential to avoid treatment denials. They often describe a waiting period for committee approval but find that high PD-L1 levels speed up the process. Many are relieved that doctors also consider compassionate use for complex cases when standard benchmarks are not met.

Do the same doctors who prescribe Keytruda in Israel also handle side-effect management, or is care transferred?

Oncologists in Israel who prescribe Keytruda typically manage your entire treatment journey including side-effect monitoring. They remain your primary contact for evaluating blood work and symptoms before infusions. While they may consult sub-specialists for specific organ issues, the oncology team coordinates all corrective care.

Primary oversight: Prescribing oncologists like Dr. Pelles Sharon lead all initial side-effect assessments.
Specialist collaboration: Oncology teams consult internal endocrinologists or pulmonologists for immune-related reactions.
Patient alert cards: Israel uses standardized cards to help other doctors report reactions back to oncologists.
Continuous monitoring: Doctors at JCI-accredited centers like Sourasky manage fatigue, rashes, and digestive issues.

Bookimed Expert Insight: Data shows that top Israeli oncologists often hold dual research and clinical trial roles. For instance, Dr. David Sarid at Sourasky Medical Center is a principal investigator for clinical trials. This means these doctors often have earlier access to updated protocols for managing complex immunotherapy reactions before they become standard global practice.

Patient Consensus: Patients note their oncologists act as a central figure for infusions and monitoring without transferring care elsewhere. They appreciate that thyroid issues or rashes are handled within the same hospital system. Many feel this approach is much more organized than having to visit separate clinics for every side effect.

How can I compare Keytruda doctors in Israel if I only have virtual consultations available?

You can compare Keytruda doctors in Israel remotely by evaluating their clinical trial leadership, specialized fellowships, and hospital affiliations. Leading oncologists at JCI-accredited centers like Sourasky Medical Center offer video consultations to review genomic profiling and design personalized immunotherapy protocols before you travel.

Clinical trial leadership: Dr. Ari Raphael at Sourasky serves as a principal investigator for Keytruda trials.
International fellowship training: Prof. Ofer Merimsky completed advanced oncology training at Institut Gustave Roussy in Paris.
Sub-specialization focus: Dr. Pelles Sharon focuses on gastrointestinal tumors while Dr. Sonnenblick specializes in breast cancer.
Consultation accessibility: Top specialists provide virtual second opinions with fees ranging from $750 to $950.

Bookimed Expert Insight: Data shows a clear distinction between general oncologists and those leading Phase I-III immunotherapy trials. For complex cases, patients should prioritize doctors like Dr. Irina Stepfansky at Sourasky, who directs oncology hospitalization and manages high-level clinical research. These specialists often have earlier access to emerging combination protocols that general practitioners may not yet utilize.

Patient Consensus: Patients note it is helpful to ask doctors specific questions about how many Keytruda cycles they have managed for a particular cancer type. They suggest recording virtual sessions to compare the confidence and phrasing of different specialists side-by-side. Many felt more secure choosing doctors tied to major institutional centers like Hadassah or Sourasky due to their strict training standards.

Хайфада ең жақсы Иммунотерапия Кейтрудой (Пембролизумаб) иммунотерапиямен кейтрудой (пембролизумаб) - ЖОҒ-1 дәрігерлер

Израиль еліндегі Иммунотерапия Кейтрудой (Пембролизумаб) бойынша үздік 3 маманнан баға ұсыныстарын алыңыз